Trial Profile

A supplementary phase 1b study to evaluate safety, tolerance and exposure of KAND567 administered intravenously in healthy subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KAND-567 (Primary)
Indications Autoimmune disorders; Breast cancer; Cancer; Cancer pain; Cardiovascular disorders; Myocardial infarction; Pancreatic cancer
Focus Adverse reactions; Pharmacokinetics
Sponsors Kancera; Novakand Pharma

Most Recent Events

22 Sep 2025 According to Kancera media release, Kancera has changed its name to Novakand Pharma.
19 Feb 2021 Status changed from recruiting to completed, according to a Kancera media release.
06 Mar 2020 Results fom the final part of this study published in the Kancera Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com